NEW YORK/LONDON (Reuters) - AstraZeneca Plc (LSE:AZN.L - News) won a U.S. court battle on Thursday over product liability claims for its blockbuster Seroquel schizophrenia treatment, the first such case to go to trial. Thousands of plaintiffs have filed lawsuits claiming that Seroquel caused their diabetes and that the drugmaker failed to adequately warn patients.
